Biovica International AB (publ)

Stockholm Stock Exchange BIOVIC-B.ST

Biovica International AB (publ) Receivables for the year ending April 30, 2024: USD 150.86 K

Biovica International AB (publ) Receivables is USD 150.86 K for the year ending April 30, 2024, a -63.91% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Biovica International AB (publ) Receivables for the year ending April 30, 2023 was USD 418.02 K, a 14.86% change year over year.
Biovica International AB (publ) Receivables for the year ending April 30, 2022 was USD 363.92 K, a 1,293.96% change year over year.
Biovica International AB (publ) Receivables for the year ending April 30, 2021 was USD 26.11 K, a 0.00% change year over year.
Biovica International AB (publ) Receivables for the year ending April 30, 2020 was USD 0.00, a -100.00% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Stockholm Stock Exchange: BIOVIC-B.ST

Biovica International AB (publ)

CEO	Mr. Anders Rylander
IPO Date	March 29, 2017
Location	Sweden
Headquarters	Dag HammarskjOelds vAeg 54B
Employees	27
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

Key trends

Past 5 years